Bieke Lambert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bieke Lambert has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Luc Defreyne
Department of Vascular and Interventional Radiology, Ghent University Hospital, Ghent, Belgium
8 shared publications Filip De Vos
Laboratory of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
4 shared publicationsKlaus Bacher
Department of Basic Medical Sciences, Ghent University, Ghent, Belgium
4 shared publicationsRoberto Troisi
Department of Hepatobiliary Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium
4 shared publications- Bieke Van Den Bossche
Maria Middelares Hospital
3 shared publications Christophe Van De Wiele
Ghent University Hospital
3 shared publications
Latest Publications
- 27 May 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (10) , 1140-1147
Impact of single photon emission computed tomography/computed tomography bone scintigraphy on the clinical management of patients with recurrent pain post spinal fusion
Objective: Persistent or recurrent pain following spinal fusion surgery presents a significant diagnostic and therapeutic challenge. This study aims to assess the clinical utility of single photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy in identifying pain generators and guiding management decisions in patients with pain occurring or persisting following spinal fusion surgery. Materials and methods: We conducted a retrospective analysis of patients who underwent a SPECT/CT 6–24 months after cervical or lumbar spinal fusion. The impact of SPECT/CT findings on clinical decision-making was evaluated based on postoperative records. We also examined a subset of nonunion cases receiving multiple SPECT/CTs over time to assess changes in bone remodeling patterns at the fusion site. Results: A total of 114 SPECT/CT scans (94 lumbar and 20 cervical) were reviewed in 106 patients and revealed pseudarthrosis with or without screw loosening (51%), adjacent level degeneration of facet joint or endplates (19%), screw irritation (12%), and extraspinal pain sources (5%). Positive SPECT/CT reports had an impact on the subsequent clinical management in 69% of cases. In 36 patients with nonunion and serial SPECT/CT scans over time, 94% showed unchanged bone remodeling patterns over time. Conclusion: SPECT/CT bone scintigraphy significantly contributed to clinical decision-making in the majority of patients with pain following spinal fusion. It effectively identified pain generators thereby guiding appropriate treatments. Furthermore, the imaging modality demonstrated a high degree of consistency in bone remodeling patterns over time. Our findings underscore the valuable role of SPECT/CT as a diagnostic adjunct in complex cases of failed back surgery syndrome.
- 27 May 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (10) , 1140-1147
Impact of single photon emission computed tomography/computed tomography bone scintigraphy on the clinical management of patients with recurrent pain post spinal fusion
Objective: Persistent or recurrent pain following spinal fusion surgery presents a significant diagnostic and therapeutic challenge. This study aims to assess the clinical utility of single photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy in identifying pain generators and guiding management decisions in patients with pain occurring or persisting following spinal fusion surgery. Materials and methods: We conducted a retrospective analysis of patients who underwent a SPECT/CT 6–24 months after cervical or lumbar spinal fusion. The impact of SPECT/CT findings on clinical decision-making was evaluated based on postoperative records. We also examined a subset of nonunion cases receiving multiple SPECT/CTs over time to assess changes in bone remodeling patterns at the fusion site. Results: A total of 114 SPECT/CT scans (94 lumbar and 20 cervical) were reviewed in 106 patients and revealed pseudarthrosis with or without screw loosening (51%), adjacent level degeneration of facet joint or endplates (19%), screw irritation (12%), and extraspinal pain sources (5%). Positive SPECT/CT reports had an impact on the subsequent clinical management in 69% of cases. In 36 patients with nonunion and serial SPECT/CT scans over time, 94% showed unchanged bone remodeling patterns over time. Conclusion: SPECT/CT bone scintigraphy significantly contributed to clinical decision-making in the majority of patients with pain following spinal fusion. It effectively identified pain generators thereby guiding appropriate treatments. Furthermore, the imaging modality demonstrated a high degree of consistency in bone remodeling patterns over time. Our findings underscore the valuable role of SPECT/CT as a diagnostic adjunct in complex cases of failed back surgery syndrome.
- 20 February 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (8) , 2979-2994
Feasibility study on the implementation of a mobile high-resolution PET/CT scanner for surgical specimens: exploring clinical applications and practical considerations
Purpose In this trial we explore potential indications of an intra-operative mobile PET/CT camera. The tested device is designed to acquire high quality images of resected tissue specimens from patients who were administered a PET-tracer, shortly before resection. Besides clinical experiences, we will also comment on the practical aspects of the implementation of a safe workflow for intra-operative PET/CT-imaging. Methods This investigator driven study involved a 12-month evaluation of the AURA 10 PET/CT camera (XEOS Medical, Belgium). Depending on the tumour type, [18F]FDG, [18F]JK-PSMA-7, [18F]PSMA-1007 or [18F]Choline was injected intravenously 60–90 min prior to the removal of the tumour. The tissue was scanned in the mobile PET/CT-device and 12 min later the surgeon could review the images. Specimen PET/CT-images were confronted with pathology findings. Dose rates were monitored around the patient throughout the procedure. Results The technique was tested in 32 surgeries for thyroid carcinomas (n = 5), transitional cell carcinomas (n = 2,) renal cell carcinoma (n = 1), prostate cancer (n = 5), breast carcinoma (n = 7), skin cancer (n = 3), nodal or bone biopsy for oncology work up (n = 6) and parathyroid adenoma (n = 3). Normalized to an injected activity of 1 MBq/kg the estimated median absorbed doses per procedure were 15.6 µSv (range 0,7-140,8) and 14,1 µSv (0,5–46,2) for respectively the surgeons and instrumenting nurses. Conclusion The overall experience of intra-operative PET/CT-imaging of surgical specimens was promising in our hospital, with particular added value in case of (para)thyroid, urological surgeries, and oncological work-ups. High quality images were obtained with low activity of tracers, enabling a safe implementation. Trial registration number (Belgium) BUN: B0172022000009 (NCT retrospectively submitted).
- 20 February 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (8) , 2979-2994
Feasibility study on the implementation of a mobile high-resolution PET/CT scanner for surgical specimens: exploring clinical applications and practical considerations
Purpose In this trial we explore potential indications of an intra-operative mobile PET/CT camera. The tested device is designed to acquire high quality images of resected tissue specimens from patients who were administered a PET-tracer, shortly before resection. Besides clinical experiences, we will also comment on the practical aspects of the implementation of a safe workflow for intra-operative PET/CT-imaging. Methods This investigator driven study involved a 12-month evaluation of the AURA 10 PET/CT camera (XEOS Medical, Belgium). Depending on the tumour type, [18F]FDG, [18F]JK-PSMA-7, [18F]PSMA-1007 or [18F]Choline was injected intravenously 60–90 min prior to the removal of the tumour. The tissue was scanned in the mobile PET/CT-device and 12 min later the surgeon could review the images. Specimen PET/CT-images were confronted with pathology findings. Dose rates were monitored around the patient throughout the procedure. Results The technique was tested in 32 surgeries for thyroid carcinomas (n = 5), transitional cell carcinomas (n = 2,) renal cell carcinoma (n = 1), prostate cancer (n = 5), breast carcinoma (n = 7), skin cancer (n = 3), nodal or bone biopsy for oncology work up (n = 6) and parathyroid adenoma (n = 3). Normalized to an injected activity of 1 MBq/kg the estimated median absorbed doses per procedure were 15.6 µSv (range 0,7-140,8) and 14,1 µSv (0,5–46,2) for respectively the surgeons and instrumenting nurses. Conclusion The overall experience of intra-operative PET/CT-imaging of surgical specimens was promising in our hospital, with particular added value in case of (para)thyroid, urological surgeries, and oncological work-ups. High quality images were obtained with low activity of tracers, enabling a safe implementation. Trial registration number (Belgium) BUN: B0172022000009 (NCT retrospectively submitted).
- 1 January 2023
- Published by Springer Nature
- p. 609-611
Foot and Ankle Bone SPECT/CT Acquisition Protocol
- 1 January 2023
- Published by Springer Nature
- p. 609-611
Foot and Ankle Bone SPECT/CT Acquisition Protocol
- 20 December 2022
- Published by Springer Nature
- p. 1-3
Foot and Ankle Bone SPECT/CT Acquisition Protocol
- 1 March 2020
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 31 (3) , S140
4:21 PM Abstract No. 307 Transarterial radioembolization versus drug-eluting beads chemoembolization for treatment of inoperable early and intermediate hepatocellular carcinoma: interim results of the randomized controlled TRACE trial
- 1 March 2020
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 31 (3) , S140
4:21 PM Abstract No. 307 Transarterial radioembolization versus drug-eluting beads chemoembolization for treatment of inoperable early and intermediate hepatocellular carcinoma: interim results of the randomized controlled TRACE trial
- 23 September 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (2) , 292-305
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0–6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of ≤3 was the most useful predictor across trials. A SIOPEN score ≤ 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores ≤3 were 47% ± 7% versus 26% ± 3% for higher scores at diagnosis (p < 0.007) and 36% ± 4% versus 14% ± 4% (p < 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores ≤3 of 51% ± 7% versus 34% ± 4% for higher scores (p < 0.001) at diagnosis and 43% ± 5% versus 16% ± 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores ≤3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score > 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.
- 23 September 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (2) , 292-305
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0–6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of ≤3 was the most useful predictor across trials. A SIOPEN score ≤ 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores ≤3 were 47% ± 7% versus 26% ± 3% for higher scores at diagnosis (p < 0.007) and 36% ± 4% versus 14% ± 4% (p < 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores ≤3 of 51% ± 7% versus 34% ± 4% for higher scores (p < 0.001) at diagnosis and 43% ± 5% versus 16% ± 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores ≤3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score > 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.
- Open Access
- 12 December 2016
- Published by Springer Nature in EJNMMI Research
- Vol. 6 (1) , 88
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab′-fragment directed against TNF. A biodistribution and dosimetry study was conducted. Tc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by exposing L929s-cells to various concentrations 99mTc-S-HYNIC CZP and measuring TNF-induced cytotoxicity. For biodistribution and dosimetry, WB images and blood and urine sampling were performed up to 24 h pi. Cumulative activities were estimated using mono-exponential fitting, and organ doses were estimated using OLINDA/EXM. The effective dose was calculated using the International Commission on Radiological Protection 103 recommendations. The uptake of the tracer in the peripheral joints was assessed visually and semiquantitatively. In vitro tests showed blocking of TNF cytotoxicity by the 99mTc-S-HYNIC CZP formulation comparable to the effect obtained with the unlabelled CZP with or without the HYNIC linker. We analysed eight patients with rheumatoid arthritis or spondyloarthritis. The highest mean absorbed organ doses were recorded for kidneys, spleen, and liver: 56 (SD 7), 34 (SD 6), and 33 (SD 7) μGy/MBq. The effective dose was 6.1 (SD 0.9) mSv for a mean injected activity of 690 (SD 35) MBq. The urinary excretion was 15.1% (SD 8.1) of the IA at 22.5 h. Blood analysis yielded a distribution half-life of 1.2 h (SD 1.5) and an elimination half-life of 26.9 h (SD 2.7). Visual analysis of the scans revealed marked tracer accumulation in the clinically affected peripheral joints. In addition, there was a statistically significant higher uptake of the tracer in the swollen joints (median uptake ratio compared to background of 3.3 in rheumatoid arthritis and 2.4 in peripheral spondyloarthritis) compared to clinically negative joints (respectively 1.3 and 1.6). We present a radiolabelling technique for CZP, a Fab′-fragment directed against TNF and currently used as a therapeutic agent in rheumatology. An effective dose of 6.1 mSv (SD 0.9) was estimated. We confirmed the uptake of this new radiopharmaceutical in clinically affected peripheral joints.
- 12 December 2016
- Published by Springer Nature in EJNMMI Research
- Vol. 6 (1) , 88
Open Access99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab′-fragment directed against TNF. A biodistribution and dosimetry study was conducted. Tc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by exposing L929s-cells to various concentrations 99mTc-S-HYNIC CZP and measuring TNF-induced cytotoxicity. For biodistribution and dosimetry, WB images and blood and urine sampling were performed up to 24 h pi. Cumulative activities were estimated using mono-exponential fitting, and organ doses were estimated using OLINDA/EXM. The effective dose was calculated using the International Commission on Radiological Protection 103 recommendations. The uptake of the tracer in the peripheral joints was assessed visually and semiquantitatively. In vitro tests showed blocking of TNF cytotoxicity by the 99mTc-S-HYNIC CZP formulation comparable to the effect obtained with the unlabelled CZP with or without the HYNIC linker. We analysed eight patients with rheumatoid arthritis or spondyloarthritis. The highest mean absorbed organ doses were recorded for kidneys, spleen, and liver: 56 (SD 7), 34 (SD 6), and 33 (SD 7) μGy/MBq. The effective dose was 6.1 (SD 0.9) mSv for a mean injected activity of 690 (SD 35) MBq. The urinary excretion was 15.1% (SD 8.1) of the IA at 22.5 h. Blood analysis yielded a distribution half-life of 1.2 h (SD 1.5) and an elimination half-life of 26.9 h (SD 2.7). Visual analysis of the scans revealed marked tracer accumulation in the clinically affected peripheral joints. In addition, there was a statistically significant higher uptake of the tracer in the swollen joints (median uptake ratio compared to background of 3.3 in rheumatoid arthritis and 2.4 in peripheral spondyloarthritis) compared to clinically negative joints (respectively 1.3 and 1.6). We present a radiolabelling technique for CZP, a Fab′-fragment directed against TNF and currently used as a therapeutic agent in rheumatology. An effective dose of 6.1 mSv (SD 0.9) was estimated. We confirmed the uptake of this new radiopharmaceutical in clinically affected peripheral joints.
- Top Cited PapersOpen Access
- 12 June 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 135
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT). Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-FS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events. With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13-25 mo) with 75% of recurring patients having ≤3 metastases. A 2nd and 3rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20-30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95% CI: 0.82 - 0.99) and ADT-FS (HR: 0.83; 95% CI: 0.71 - 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients. Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.
- 12 June 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 135
Top Cited PapersOpen AccessRepeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT). Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-FS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events. With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13-25 mo) with 75% of recurring patients having ≤3 metastases. A 2nd and 3rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20-30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95% CI: 0.82 - 0.99) and ADT-FS (HR: 0.83; 95% CI: 0.71 - 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients. Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.
- Open Access
- 23 August 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 144
Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation. A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage). Transarterial loco regional treatment modalities offer palliative treatment options for these patients; transarterial chemoembolization (TACE) is the current standard treatment. During TACE, a catheter is advanced into the branches of the hepatic artery supplying the tumor, and a combination of embolic material and chemotherapeutics is delivered through the catheter directly into the tumor. Yttrium-90 radioembolization (90Y-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor. 90Y-RE is increasingly used in clinical practice for treatment of intermediate stage hepatocellular carcinoma, but its efficacy has never been prospectively compared to that of the standard treatment (TACE). In this study, we describe the protocol of a multicenter randomized controlled trial aimed at comparing the effectiveness of TACE and 90Y-RE for treatment of patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma. Methods/design: In this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group performance status 0 to 1 and Child-Pugh A to B will be randomly assigned to either 90Y-RE or TACE with drug eluting beads. Patients assigned to 90Y-RE will first receive a diagnostic angiography, followed by the actual transarterial treatment, which can be divided into two sessions in case of bilobar disease. Patients assigned to TACE will receive a maximum of three consecutive transarterial treatment sessions. Patients will undergo structural follow-up for a timeframe of two years post treatment. Post procedural magnetic resonance imaging (MRI) will be performed at one and three months post trial entry and at three-monthly intervals thereafter for two years to assess tumor response. Primary outcome will be time to progression. Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness. Trial registration: NCT01381211
- 23 August 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 144
Open AccessTransarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation. A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage). Transarterial loco regional treatment modalities offer palliative treatment options for these patients; transarterial chemoembolization (TACE) is the current standard treatment. During TACE, a catheter is advanced into the branches of the hepatic artery supplying the tumor, and a combination of embolic material and chemotherapeutics is delivered through the catheter directly into the tumor. Yttrium-90 radioembolization (90Y-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor. 90Y-RE is increasingly used in clinical practice for treatment of intermediate stage hepatocellular carcinoma, but its efficacy has never been prospectively compared to that of the standard treatment (TACE). In this study, we describe the protocol of a multicenter randomized controlled trial aimed at comparing the effectiveness of TACE and 90Y-RE for treatment of patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma. Methods/design: In this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group performance status 0 to 1 and Child-Pugh A to B will be randomly assigned to either 90Y-RE or TACE with drug eluting beads. Patients assigned to 90Y-RE will first receive a diagnostic angiography, followed by the actual transarterial treatment, which can be divided into two sessions in case of bilobar disease. Patients assigned to TACE will receive a maximum of three consecutive transarterial treatment sessions. Patients will undergo structural follow-up for a timeframe of two years post treatment. Post procedural magnetic resonance imaging (MRI) will be performed at one and three months post trial entry and at three-monthly intervals thereafter for two years to assess tumor response. Primary outcome will be time to progression. Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness. Trial registration: NCT01381211
- Open Access
- 1 May 2012
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 22 (4) , 630-637
Value of Magnetic Resonance and FDG PET-CT in Predicting Tumor Response and Resectability of Primary Locally Advanced Cervical Cancer After Treatment With Intensity-Modulated Arc Therapy
- 1 May 2012
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 22 (4) , 630-637
Open AccessValue of Magnetic Resonance and FDG PET-CT in Predicting Tumor Response and Resectability of Primary Locally Advanced Cervical Cancer After Treatment With Intensity-Modulated Arc Therapy